Partnership Opportunities

Looking To Position Yourself as a Leader Within the CNS Space?

Following an exciting year of progress in Alzheimer’s approvals, excitement grows for the next generation of disease-modifying neurodegeneration-targeted drugs. From large pharma heavyweights to well-established and new, innovative biotechs, the whole of biopharma has its purse strings at the ready to invest in the right services to optimize its pipeline strategy. In a field where biopharma trusts their long-standing go-to's, how can you
leverage the unique value your service will offer?

This April, connect with an exclusive group of 150+ senior decision makers at the 12th Alzheimer’s & Parkinson’s Drug Development Summit, a meeting built by industry for industry to tackle the hottest challenges from a lens of biopharma challenges and innovations. Are you ready to elevate your unique value proposition in overcoming their pipeline bottlenecks?

There are a limited number of partnerships available, including speaking positions across the full agenda, reserved exclusively for high-quality companies. If you provide services in assay development, neuroimaging, drug discovery, digital biomarkers, in vitro or in vivo modeling, or clinical CRO services that would benefit this niche audience of Alzheimer’s & Parkinson’s decision-makers, now is the time to secure new business and form lasting connections with the companies seeking solutions to progress their products to market.

Biopharma Drug Developers Need Your Help With:

Fluid/Assay Biomarkers


Digital Biomarkers

In Vitro Models

In Vitro Models & Preclinical CROs

Clinical CROs

Drug Delivery

Discovery & AI

Who Could You Meet?

APDD - companies attending - logo cloud

Why Partner?

graphic number - 1
graphic number - 2
graphic number - 3
graphic number - 4
graphic number - 5

Build connections with your target audience you’ve been looking to meet from senior CNS decision makers from large pharma increasing their spend in neuroscience R&D, to well established and new biotechs expanding their neurodegeneration pipelines


Gain brand visibility: broaden your company’s exposure to our intimate audience of 150+ senior biopharma leaders you won’t see at ADPD or CTAD

Educate the industry: speak on the main agenda to leverage your expertise alongside senior KOLs from biopharma to gain credibility and build trust, distinguishing your unique value proposition from your competitors

Secure new business with exclusive market insights selectively curated by the Hanson Wade team to get into the crux of your customers’ pain points and differentiate your brand as what your customers are looking for

Cement your company as the leading provider for your service in neurodegenerative research and development

Who Will You Meet?

Graph 1
Graph 2

Become a Partner

Ben Walls

Partnerships Director